
ICD-O-3 Morphology
Effective
2010 and later
Reportable
for cases diagnosed
2010 and later
Primary Site(s)
See Module 7
Most common sites of involvement: lymph nodes (C770-C779)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010 see code 9680/3.)
The lymphoma characteristically involves lymph nodes and spleen but can disseminate to other viscera via the blood stream in which rarely it manifests as a leukemia.
The term "plasmablastic" is used for this lymphoma because the cells resemble plasma cells and have abundant immunoglobulin, but they lack IG somatic hyper-mutation.
This lymphoma is considered to be the same primary with the following:
1. Plasmablastic lymphoma (9735/3). The two diagnosis can be distinguished because plasmablastic lymphoma frequently show class-switched and hyper-mutated IG genes.
2. Primary effusion lymphoma (9678/3) may complicate HHV8 MCD but PEL neoplastic cells do no express immunoglobulin and are usually co-infected with EBV.
This is a very aggressive lymphoma with a median survival of a few months.
Note: Castleman disease by itself is not reportable.
The lymphoma characteristically involves lymph nodes and spleen but can disseminate to other viscera via the blood stream in which rarely it manifests as a leukemia.
The term "plasmablastic" is used for this lymphoma because the cells resemble plasma cells and have abundant immunoglobulin, but they lack IG somatic hyper-mutation.
This lymphoma is considered to be the same primary with the following:
1. Plasmablastic lymphoma (9735/3). The two diagnosis can be distinguished because plasmablastic lymphoma frequently show class-switched and hyper-mutated IG genes.
2. Primary effusion lymphoma (9678/3) may complicate HHV8 MCD but PEL neoplastic cells do no express immunoglobulin and are usually co-infected with EBV.
This is a very aggressive lymphoma with a median survival of a few months.
Note: Castleman disease by itself is not reportable.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
Definition
HHV8-positive diffuse large B-cell lymphoma, NOS, usually arises in association with HHV8-positive multicentric Castleman disease (MCD). The lymphoma is characterized by a monoclonal proliferation of HHV8-infected lymphoid cells resembling plasmablasts expressing IgM lambda. It is usually associated with HIV infection.
Definitive Diagnostic Methods
Genetic testing
Histologic confirmation
Immunophenotyping
Genetics Data
IG genes are unmutated
Immunophenotyping
CD20 positive or negative
CD27-
CD38 positive or negative
CD79a-
CD138-
cIgA positive
cIgM negative
cIgM with lambda light chain restriction strongly expressed
Epstein-Barr encoded RNA (EBER)-negative
Nuclear staining for interleukin-6
Nuclear staining for LANA-1
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Immunotherapy
Surgery
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-9 Codes
200.7 Large cell lymphoma
Corresponding ICD-10 Codes
C83.3 Non-Hodgkin lymphoma large cell (diffuse)
Corresponding ICD-10-CM Codes (U.S. only)
C83.3 Diffuse large B-cell lymphoma (effective October 01, 2015)
D47.Z2 Castleman disease (effective October 01, 2015)
Signs and Symptoms
Drenching night sweats
Enlarged lymph nodes
Fatigue
Fever (for no known reason)
Manifestations of Kaposi Sarcoma
Massive splenogmegaly
Painless swelling in the lymph nodes
Profound immunodeficiency
Skin rash or itchy skin
Weight loss (for no known reason)
Diagnostic Exams
Blood chemistry studies
CT (CAT) scan
Cytogenetic analysis
Flow cytometry
Immunohistochemistry
Immunophenotyping
Laparoscopy (rarely performed)
Laparotomy (rarely performed)
Lymph node biopsy
PET (positron emission tomography) scan
Progression and Transformation
None
Epidemiology and Mortality
Country: most common in African and Mediterranean countries
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 327-328
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 327-328
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
